Pharmafile Logo

Peter Impey

- PMLiVE

Creating a culture of inclusion

By Sarah Pollard and Claire Poynton

- PMLiVE

Pfizer’s one-time haemophilia B therapy Durveqtix receives CHMP recommendation

More than 38,000 people worldwide are currently affected by the inherited bleeding disorder

- PMLiVE

Moderna/Merck share positive three-year results for investigational skin cancer vaccine

More than 100,000 new cases of melanoma are expected to be diagnosed in the US in 2024

- PMLiVE

Takeda’s enzyme replacement therapy recommended by CHMP for rare blood clotting disorder cTTP

If approved, rADAMTS13 will be the first and only enzyme replacement therapy in the EU indicated for cTTP

- PMLiVE

Eli Lilly commits further $6.5m to UNICEF for young people at risk of noncommunicable diseases

The new funding builds on the company’s initial commitment of $14.4m in 2022

- PMLiVE

Driving diversity in clinical research

The positive impact of technology-enabled trials in ensuring equal representation for all

- PMLiVE

Natural intelligence: healthcare comms in 2024

By Clare Middleton and Katie McMorran

- PMLiVE

De-mystifying the NHS – What you need to know about the NHS as a market for your health technology

Are you a global market access lead looking to understand the challenges faced by your UK affiliates? Or do you work at a national level with responsibility for bringing a...

Petauri Evidence

- PMLiVE

How to hack a problem like healthcare

To create the most compelling clinical and cost-benefit arguments, the quickest and most comprehensive answers come by ‘bringing the outside in’ and treating the problem as a ‘hack’.

EatMoreFruit

AMICULUM: Activating science, transforming health

From 4 June 2024 AMICULUM is bringing together our family of agencies under the AMICULUM® brand. All of our agencies were founded and owned by AMICULUM and the business continues...

Amiculum

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links